A Multi-Center, Randomized, Double-Blind, Placebo- Controlled Clinical Trial of the Safety and Efficacy of Convalescent Plasma for the Treatment of COVID-19 in Hospitalized Patients in Lagos State

Abayomi et al., PACTR202006760881890, LACCPT, PACTR202006760881890, Nov 2021
Late treatmentRCT · PACTR202006760881890 · 22 patients · Nigeria
Conv. Plasma for COVID-19
LACCPT Abayomi et al. PACTR202006760881890 · November 2021
Outcome
Improvement
Relative Risk · 95% CI
Mortality
-17%1.17 · 0.58–2.35
00.511.52+
← Convalescent
Plasma reduces riskIncreased risk →
Trial underpowered to detect differences
RCT 22 hospitalized patients, show no significant difference in mortality with convalescent plasma. Results are from Axfors et al..
Important missing comments or errors? Let us know.
risk of death, 16.7% higher, RR 1.17, p = 1.00, treatment 7 of 11 (63.6%), control 6 of 11 (54.5%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Abayomi et al., 20 Nov 2021, Double Blind Randomized Controlled Trial, placebo-controlled, Nigeria, peer-reviewed, 1 author, trial PACTR202006760881890 (LACCPT).
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org October 2026 Nigeria Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil France Italy Canada Pakistan Spain Vietnam Japan Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Taiwan Fiji Zambia Bosnia-Herzegovina Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia Nigeria favored low-cost treatments.The average efficacy of treatments was high.Low-cost treatments improve early treatment, andprovide complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org October 2026 Nigeria Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil France Italy Canada Pakistan Spain Vietnam Japan Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Taiwan Fiji Zambia Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia Nigeria favored low-cost treatments.The average efficacy was high.Low-cost protocols improve early treatment,and add complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0